Session » Epidemiology and Public Health Poster III

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1777

A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information

1:00PM-3:00PM: Abstract Number: 1756

Adverse Events in Patients with Inflammatory Joint Diseases: Results from the EULAR Coronavirus Vaccine (COVAX) Physician-reported Registry

1:00PM-3:00PM: Abstract Number: 1786

Anterior Knee Pain Is Associated with 2-year Compartment Specific Patellofemoral Cartilage Worsening: The MOST Study

1:00PM-3:00PM: Abstract Number: 1750

Association Between Appendicitis and the Risk of Systemic Lupus Erythematosus: A Population-based, Case-control Study

1:00PM-3:00PM: Abstract Number: 1754

Association of Cognitive Impairment and Symptomatic Lower Extremity Osteoarthritis by Level of Physical Activity: Preliminary Data from the Johnston County Health Study

1:00PM-3:00PM: Abstract Number: 1752

Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER

1:00PM-3:00PM: Abstract Number: 1769

Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data

1:00PM-3:00PM: Abstract Number: 1776

COVID-19 Cases in Patients Treated with Secukinumab: Analysis from the Global Safety Database

1:00PM-3:00PM: Abstract Number: 1766

COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis

1:00PM-3:00PM: Abstract Number: 1760

Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19

1:00PM-3:00PM: Abstract Number: 1751

Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management

1:00PM-3:00PM: Abstract Number: 1763

Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination

1:00PM-3:00PM: Abstract Number: 1773

Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US

1:00PM-3:00PM: Abstract Number: 1767

Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study

1:00PM-3:00PM: Abstract Number: 1783

Exploring How and Why Organizations Identify, Adopt, Disseminate, and Sustain Evidence-based Programs for Latinos with Arthritis

1:00PM-3:00PM: Abstract Number: 1759

Factors Affecting Success of Behavioral Interventions to Improve Physical Activity in Patients with Knee Osteoarthritis

1:00PM-3:00PM: Abstract Number: 1784

Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study

1:00PM-3:00PM: Abstract Number: 1780

Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases

1:00PM-3:00PM: Abstract Number: 1755

Improving Quality of Life Through Connection: A Scoping Review of Peer Coaching Interventions in the Field of Rheumatology

1:00PM-3:00PM: Abstract Number: 1758

Intake of Dairy Products as a Risk Factor for Rheumatoid Arthritis; A Nested Case-Control Study

1:00PM-3:00PM: Abstract Number: 1781

Knee Pain Is Highly Associated with Ankle/Foot Pain, Arch Height, and Arch Flexibility: The Johnston County Osteoarthritis Project

1:00PM-3:00PM: Abstract Number: 1775

More Than Half of Patients with Osteoarthritis Have Positive Screening for Fibromyalgia And/or Depression, Feasibly Assessed in Routine Care on Indices Within a Single MDHAQ (multidimensional Health Assessment Questionnaire)

1:00PM-3:00PM: Abstract Number: 1778

More Than Half of RA Patients with a Lifetime History of Mood Disorders or Anxious and Depressed During COVID-19 Pandemic

1:00PM-3:00PM: Abstract Number: 1774

Performance of an Early Triage System for Identification of Patients with Inflammatory Rheumatic Diseases

1:00PM-3:00PM: Abstract Number: 1770

Prevalence and Incidence of Depression in Patients with Rheumatoid Arthritis: A Systematic Review

1:00PM-3:00PM: Abstract Number: 1785

PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort

1:00PM-3:00PM: Abstract Number: 1779

Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort

1:00PM-3:00PM: Abstract Number: 1765

Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs

1:00PM-3:00PM: Abstract Number: 1768

Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study

1:00PM-3:00PM: Abstract Number: 1782

Sociocultural and Moral Factors Influencing the Decision to Vaccinate Among Rheumatic Patients: A Qualitative Study

1:00PM-3:00PM: Abstract Number: 1762

Stability of Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-CoV-2 Pandemic and Vaccination Campaigns

1:00PM-3:00PM: Abstract Number: 1753

Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database

1:00PM-3:00PM: Abstract Number: 1771

The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

1:00PM-3:00PM: Abstract Number: 1757

The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease Among Women – a Prospective Cohort Analysis of Women over 34 Years

1:00PM-3:00PM: Abstract Number: 1761

Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1764

Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].